Ponatinib (BioDeep_00000169693)

   

human metabolite


代谢物信息卡片


3-(2-(imidazo(1,2-b)Pyridazin-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-y-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide

  化学式: C29H27F3N6O (532.2198)
中文名称: 帕纳替尼
  谱图信息: 最多检出来源 not specific(not specific) %

分子结构信息

SMILES: CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5
InChI: InChI=1S/C29H27F3N6O/c1-20-5-6-22(16-21(20)8-10-25-18-33-27-4-3-11-34-38(25)27)28(39)35-24-9-7-23(26(17-24)29(30,31)32)19-37-14-12-36(2)13-15-37/h3-7,9,11,16-18H,12-15,19H2,1-2H3,(H,35,39)


描述信息

Ponatinib is a Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012 (DB08901).
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EA - Bcr-abl tyrosine kinase inhibitors
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C93259 - VEGFR Tyrosine Kinase Inhibitor
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163790 - Flt-3-targeting Agent
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163953 - VEGFR-targeting Agent
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164037 - PDGFR-targeting Agent
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163999 - cKIT-targeting Agent
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C159198 - c-KIT Inhibitor
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164035 - FGFR-targeting Agent
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C155727 - FGFR Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C159438 - RET Inhibitor
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C155700 - BCR-ABL Inhibitor
D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors
D000970 - Antineoplastic Agents

同义名列表

36 个代谢物同义名

3-(2-(imidazo(1,2-b)Pyridazin-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-y-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide; 3-(2-{imidazo[1,2-b]pyridazin-3-yl}ethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide; Ponatinib hydrochloride; Ponatinib (AP24534); Ponatinibum; Ponatinib; AP 24534; AP24534; Iclusig; PONATINIB [WHO-DD]; 0LI; 3-(2-(Imidazo(1,2-b)pyridazin-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1- yl)methyl)-3-(trifluoromethyl)phenyl)benzamide; 3-(2-(IMIDAZO(1,2-B)PYRIDAZIN-3-YL)ETHYNYL)-4-METHYL-N-(4-((4-METHYLPIPERAZIN-1-YL)METHYL)-3-(TRIFLUOROMETHYL)PHENYL)BENZAMIDE; 3-(2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide; 3-(2-Imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]benzamide; 3-(2-Imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]benzamide;AP 2453 4; 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide; 3-(imidazo(1,2-b)pyridazin-3-ylethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide; 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide; 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide.; 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzam; 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzam ide; 3-(Imidazo[1,2-B]pyridazin-3-Ylethynyl)-4-Methyl-N-{4-[(4-Methylpiperazin-1-Yl)methyl]-3-(Trifluoromethyl)phenyl}benzamide; 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide; Benzamide, 3-(2-imidazo(1,2-b)pyridazin-3-ylethynyl)-4-methyl-N-(4-((4-methyl-1- piperazinyl)methyl)-3-(trifluoromethyl)phenyl)-; Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1-Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl); BENZAMIDE, 3-(2-IMIDAZO(1,2-B)PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-(4-((4-METHYL-1-PIPERAZINYL)METHYL)-3-(TRIFLUOROMETHYL)PHENYL)-; Benzamide, 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-; 3-(2-Imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]benzamide; AP 24534; Iclusig; Ponatinib; L01XE24; Ponatinib (Standard); Ponatinib (USAN/INN); PONATINIB [INN]; PONATINIB [MI]; Ponatinib [USAN:INN]; Ponatinib [USAN]; PONATINIB [VANDF]



数据库引用编号

9 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome()

BioCyc()

PlantCyc()

代谢反应

个相关的代谢反应过程信息。

Reactome()

BioCyc()

WikiPathways()

Plant Reactome()

INOH()

PlantCyc()

COVID-19 Disease Map()

PathBank()

PharmGKB()

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表


文献列表

  • Yali Wu, Yunnan Ma, Wanling Zhong, Huijuan Shen, Jinhong Ye, Shouying Du, Pengyue Li. Alleviation of endothelial dysfunction of Pheretima guillemi (Michaelsen)-derived protein DPf3 in ponatinib-induced thrombotic zebrafish and mechanisms explored through ox-LDL-induced HUVECs and TMT-based proteomics. Journal of ethnopharmacology. 2024 Apr; 323(?):117669. doi: 10.1016/j.jep.2023.117669. [PMID: 38159828]
  • Shenghua Lin, Xin Liu, Aonan Sun, Huiliang Liang, Zhen Li, Suyan Ye, Honglin Ma, Wei Fan, Chuanlin Shen, Meng Jin, Qiuxia He. Qilong capsule alleviates ponatinib-induced ischemic stroke in a zebrafish model by regulating coagulation, inflammation and apoptosis. Journal of ethnopharmacology. 2023 Oct; 314(?):116397. doi: 10.1016/j.jep.2023.116397. [PMID: 37086871]
  • Yue Gao, Yue Ding, Xin-Ran Tai, Chen Zhang, Dong Wang. Ponatinib: An update on its drug targets, therapeutic potential and safety. Biochimica et biophysica acta. Reviews on cancer. 2023 09; 1878(5):188949. doi: 10.1016/j.bbcan.2023.188949. [PMID: 37399979]
  • Yang Zhou, Shuang Xiang, Fang Yang, Xiaoyun Lu. Targeting Gatekeeper Mutations for Kinase Drug Discovery. Journal of medicinal chemistry. 2022 12; 65(23):15540-15558. doi: 10.1021/acs.jmedchem.2c01361. [PMID: 36395392]
  • Evan Flietner, Zhi Wen, Adhithi Rajagopalan, Oisun Jung, Lyndsay Watkins, Joshua Wiesner, Xiaona You, Yun Zhou, Yuqian Sun, Brock Kingstad-Bakke, Natalie S Callander, Alan Rapraeger, M Suresh, Fotis Asimakopoulos, Jing Zhang. Ponatinib sensitizes myeloma cells to MEK inhibition in the high-risk VQ model. Scientific reports. 2022 06; 12(1):10616. doi: 10.1038/s41598-022-14114-z. [PMID: 35739276]
  • Suzanne George, Margaret von Mehren, Jonathan A Fletcher, Jichao Sun, Sen Zhang, Justin R Pritchard, John Graeme Hodgson, David Kerstein, Victor M Rivera, Frank G Haluska, Michael C Heinrich. Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022 04; 28(7):1268-1276. doi: 10.1158/1078-0432.ccr-21-2037. [PMID: 35091442]
  • Michael J Hanley, Paul M Diderichsen, Narayana Narasimhan, Shouryadeep Srivastava, Neeraj Gupta, Karthik Venkatakrishnan. Population Pharmacokinetics of Ponatinib in Healthy Adult Volunteers and Patients With Hematologic Malignancies and Model-Informed Dose Selection for Pediatric Development. Journal of clinical pharmacology. 2022 04; 62(4):555-567. doi: 10.1002/jcph.1990. [PMID: 34699069]
  • Mona E El Sharkasy, Rasha Aboshabana, F Belal, M Walash, Manar M Tolba. Synchronized spectrofluorimetric determination of ponatinib and curcumin as an effective therapeutic combination in laboratory prepared mixtures and human plasma samples. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy. 2022 Jan; 264(?):120235. doi: 10.1016/j.saa.2021.120235. [PMID: 34371314]
  • Zhen Zhang, Yongjin Wang, Xiaojuan Chen, Xiaojuan Song, Zhengchao Tu, Yongheng Chen, Zhimin Zhang, Ke Ding. Characterization of an aromatic trifluoromethyl ketone as a new warhead for covalently reversible kinase inhibitor design. Bioorganic & medicinal chemistry. 2021 11; 50(?):116457. doi: 10.1016/j.bmc.2021.116457. [PMID: 34670167]
  • Michela Puxeddu, Hongliang Shen, Ruoli Bai, Antonio Coluccia, Marianna Bufano, Marianna Nalli, Jessica Sebastiani, Diego Brancaccio, Eleonora Da Pozzo, Chiara Tremolanti, Claudia Martini, Viviana Orlando, Stefano Biagioni, Maria Stefania Sinicropi, Jessica Ceramella, Domenico Iacopetta, Addolorata Maria Luce Coluccia, Ernest Hamel, Te Liu, Romano Silvestri, Giuseppe La Regina. Discovery of pyrrole derivatives for the treatment of glioblastoma and chronic myeloid leukemia. European journal of medicinal chemistry. 2021 Oct; 221(?):113532. doi: 10.1016/j.ejmech.2021.113532. [PMID: 34052717]
  • Gabriella Mezei, Péter Batár, Laura Kozma, Árpád Illés, János Kappelmayer, Ildikó Beke Debreceni. Ponatinib Exerts an Inhibitory Effect on Collagen-induced Platelet Aggregation and Generation of Coated-Platelets. Anticancer research. 2021 Oct; 41(10):4867-4874. doi: 10.21873/anticanres.15300. [PMID: 34593434]
  • Marina Chan, Siddharth Vijay, John McNevin, M Juliana McElrath, Eric C Holland, Taranjit S Gujral. Machine learning identifies molecular regulators and therapeutics for targeting SARS-CoV2-induced cytokine release. Molecular systems biology. 2021 09; 17(9):e10426. doi: 10.15252/msb.202110426. [PMID: 34486798]
  • Yuji Mukai, Yuka Yoshida, Tatsunari Yoshida, Takeshi Kondo, Nobuo Inotsume, Takaki Toda. Simultaneous Quantification of BCR-ABL and Bruton Tyrosine Kinase Inhibitors in Dried Plasma Spots and Its Application to Clinical Sample Analysis. Therapeutic drug monitoring. 2021 06; 43(3):386-393. doi: 10.1097/ftd.0000000000000825. [PMID: 33065614]
  • Hua Tu, Yuan-Jing Zhou, Li-Jing Tang, Xiao-Ming Xiong, Xiao-Jie Zhang, Md Sayed Ali Sheikh, Jie-Jie Zhang, Xiu-Ju Luo, Chuang Yuan, Jun Peng. Combination of ponatinib with deferoxamine synergistically mitigates ischemic heart injury via simultaneous prevention of necroptosis and ferroptosis. European journal of pharmacology. 2021 May; 898(?):173999. doi: 10.1016/j.ejphar.2021.173999. [PMID: 33675785]
  • Maiko Abumiya, Naoto Takahashi, Tomoko Yoshioka, Yoshihiro Kameoka, Masatomo Miura. Evaluation of the plasma concentration of ponatinib in a chronic myeloid leukaemia patient with ponatinib intolerance. Journal of clinical pharmacy and therapeutics. 2021 Feb; 46(1):219-222. doi: 10.1111/jcpt.13257. [PMID: 32985698]
  • Keith C S Sia, Ling Zhong, Chelsea Mayoh, Murray D Norris, Michelle Haber, Glenn M Marshall, Mark J Raftery, Richard B Lock. Targeting TSLP-Induced Tyrosine Kinase Signaling Pathways in CRLF2-Rearranged Ph-like ALL. Molecular cancer research : MCR. 2020 12; 18(12):1767-1776. doi: 10.1158/1541-7786.mcr-19-1098. [PMID: 32801162]
  • Satoru Nanno, Kana Matsumoto, Mika Nakamae, Hiroshi Okamura, Mitsutaka Nishimoto, Asao Hirose, Hideo Koh, Yasuhiro Nakashima, Takahiko Nakane, Kunihiko Morita, Masayuki Hino, Hirohisa Nakamae. Effect of Prophylactic Post-transplant Ponatinib Administration on Outcomes in Patients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia. Clinical lymphoma, myeloma & leukemia. 2020 12; 20(12):813-819.e1. doi: 10.1016/j.clml.2020.07.005. [PMID: 32800519]
  • Xiaoyun Lu, Jeff B Smaill, Ke Ding. Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations. Journal of medicinal chemistry. 2020 10; 63(19):10726-10741. doi: 10.1021/acs.jmedchem.0c00507. [PMID: 32432477]
  • Bernhard Englinger, Anna Laemmerer, Patrick Moser, Sebastian Kallus, Clemens Röhrl, Christine Pirker, Dina Baier, Thomas Mohr, Laura Niederstaetter, Samuel M Meier-Menches, Christopher Gerner, Lisa Gabler, Johannes Gojo, Gerald Timelthaler, Julia Senkiv, Walter Jäger, Christian R Kowol, Petra Heffeter, Walter Berger. Lipid droplet-mediated scavenging as novel intrinsic and adaptive resistance factor against the multikinase inhibitor ponatinib. International journal of cancer. 2020 09; 147(6):1680-1693. doi: 10.1002/ijc.32924. [PMID: 32064608]
  • Giovanni Caocci, Olga Mulas, Isabella Capodanno, Elisabetta Abruzzese, Alessandra Iurlo, Luigiana Luciano, Francesco Albano, Mario Annunziata, Mario Tiribelli, Massimiliano Bonifacio, Sara Galimberti, Fausto Castagnetti, Nicola Sgherza, Fabio Stagno, Antonella Gozzini, Ester Maria Orlandi, Debora Luzi, Gianni Binotto, Patrizia Pregno, Claudio Fozza, Fabio Efficace, Maria Pina Simula, Malgorzata Monika Trawinska, Daniele Cattaneo, Fiorenza De Gregorio, Immacolata Attolico, Rossella Stella, Luigi Scaffidi, Claudia Baratè, Gabriele Gugliotta, Emilia Scalzulli, Chiara Elena, Francesca Pirillo, Robin Foà, Massimo Breccia, Giorgio La Nasa. Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study. Blood cancer journal. 2020 06; 10(6):66. doi: 10.1038/s41408-020-0333-2. [PMID: 32514110]
  • Chandrayee Ghosh, Suresh Kumar, Yevgeniya Kushchayeva, Kelli Gaskins, Myriem Boufraqech, Darmood Wei, Sudheer Kumar Gara, Lisa Zhang, Ya-Qin Zhang, Min Shen, Sanjit Mukherjee, Electron Kebebew. A Combinatorial Strategy for Targeting BRAF V600E-Mutant Cancers with BRAFV600E Inhibitor (PLX4720) and Tyrosine Kinase Inhibitor (Ponatinib). Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 04; 26(8):2022-2036. doi: 10.1158/1078-0432.ccr-19-1606. [PMID: 31937621]
  • Syed O Amin, Marcel Ruzicka, Kevin D Burns, Isabelle A Bence-Bruckler, Stephen E Ryan, Adnan Hadziomerovic, Swapnil Hiremath. Renovascular hypertension from the BCR-ABL tyrosine kinase inhibitor ponatinib. Journal of clinical hypertension (Greenwich, Conn.). 2020 04; 22(4):678-682. doi: 10.1111/jch.13843. [PMID: 32175644]
  • Pierantonio Menna, Ugo De Grazia, Francesco Marchesi, Giorgio Minotti, Emanuela Salvatorelli. Further Analytical, Pharmacokinetic, and Clinical Observations on Low-Dose Ponatinib in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Chemotherapy. 2020; 65(1-2):35-41. doi: 10.1159/000509639. [PMID: 32829325]
  • Eudocia Q Lee, Alona Muzikansky, Dan G Duda, Sarah Gaffey, Jorg Dietrich, Lakshmi Nayak, Ugonma N Chukwueke, Rameen Beroukhim, Lisa Doherty, Caroline Kane Laub, Debra LaFrankie, Brittney Fontana, Jennifer Stefanik, Sandra Ruland, Victoria Caruso, Jennifer Bruno, Keith Ligon, David A Reardon, Patrick Y Wen. Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma. Cancer medicine. 2019 10; 8(13):5988-5994. doi: 10.1002/cam4.2505. [PMID: 31444999]
  • Daniel A Polasky, Sugyan M Dixit, Daniel D Vallejo, Kathryn D Kulju, Brandon T Ruotolo. An Algorithm for Building Multi-State Classifiers Based on Collision-Induced Unfolding Data. Analytical chemistry. 2019 08; 91(16):10407-10412. doi: 10.1021/acs.analchem.9b02650. [PMID: 31310505]
  • Abdullah Hamadi, Andrew P Grigg, Gasim Dobie, Kate L Burbury, Anthony P Schwarer, Faith A Kwa, Denise E Jackson. Ponatinib Tyrosine Kinase Inhibitor Induces a Thromboinflammatory Response. Thrombosis and haemostasis. 2019 Jul; 119(7):1112-1123. doi: 10.1055/s-0039-1688787. [PMID: 31079415]
  • Saad Tayyab, Si Enn Sam, Md Zahirul Kabir, Nor Farrah Wahidah Ridzwan, Saharuddin B Mohamad. Molecular interaction study of an anticancer drug, ponatinib with human serum albumin using spectroscopic and molecular docking methods. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy. 2019 May; 214(?):199-206. doi: 10.1016/j.saa.2019.02.028. [PMID: 30780089]
  • Yuta Yamamoto, Tetsuya Saita, Rintaro Sogawa, Kenji Ogata, Yutaro Yamamoto, Sakiko Kimura, Yutaka Narisawa, Shinya Kimura, Masashi Shin. Development of a sandwich enzyme-linked immunosorbent assay for the quantification of ponatinib in serum. Analytical biochemistry. 2019 04; 571(?):14-20. doi: 10.1016/j.ab.2019.02.010. [PMID: 30771339]
  • Michelina Santopietro, Maurizio Miano, Giovanna Palumbo, Kejian Zhang, Luisa Cardarelli, Sabina Chiaretti, Nadia Peragine, Mauro Nanni, Daniela Diverio, Francesca Mancini, Anna Maria Testi, Maria Luisa Moleti, Robin Foà, Fiorina Giona. Atypical Chronic Myeloid Leukemia in a Patient with Aplastic Anemia. Acta haematologica. 2019; 142(3):185-186. doi: 10.1159/000497137. [PMID: 31112981]
  • Masatomo Miura, Naoto Takahashi. [Management using the plasma concentration of tyrosine kinase inhibitors for the treatment of chronic myelogenous leukemia: an update]. [Rinsho ketsueki] The Japanese journal of clinical hematology. 2019; 60(9):1140-1147. doi: 10.11406/rinketsu.60.1140. [PMID: 31597837]
  • Johannes W Bigenzahn, Giovanna M Collu, Felix Kartnig, Melanie Pieraks, Gregory I Vladimer, Leonhard X Heinz, Vitaly Sedlyarov, Fiorella Schischlik, Astrid Fauster, Manuele Rebsamen, Katja Parapatics, Vincent A Blomen, André C Müller, Georg E Winter, Robert Kralovics, Thijn R Brummelkamp, Marek Mlodzik, Giulio Superti-Furga. LZTR1 is a regulator of RAS ubiquitination and signaling. Science (New York, N.Y.). 2018 12; 362(6419):1171-1177. doi: 10.1126/science.aap8210. [PMID: 30442766]
  • Elias Jabbour, Nicholas J Short, Farhad Ravandi, Xuelin Huang, Naval Daver, Courtney D DiNardo, Marina Konopleva, Naveen Pemmaraju, William Wierda, Guillermo Garcia-Manero, Koji Sasaki, Jorge Cortes, Rebecca Garris, Joseph D Khoury, Jeffrey Jorgensen, Nitin Jain, Joie Alvarez, Susan O'Brien, Hagop Kantarjian. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. The Lancet. Haematology. 2018 Dec; 5(12):e618-e627. doi: 10.1016/s2352-3026(18)30176-5. [PMID: 30501869]
  • Phillip A Wages, Hye-Young H Kim, Zeljka Korade, Ned A Porter. Identification and characterization of prescription drugs that change levels of 7-dehydrocholesterol and desmosterol. Journal of lipid research. 2018 10; 59(10):1916-1926. doi: 10.1194/jlr.m086991. [PMID: 30087204]
  • Mohamed W Attwa, Adnan A Kadi, Hany W Darwish, Sawsan M Amer, Haitham AlRabiah. LC-ESI-MS/MS identification and characterization of ponatinib in vivo phase I and phase II metabolites. Clinica chimica acta; international journal of clinical chemistry. 2018 Oct; 485(?):144-151. doi: 10.1016/j.cca.2018.06.035. [PMID: 29966620]
  • Janice K Laramy, Minjee Kim, Karen E Parrish, Jann N Sarkaria, William F Elmquist. Pharmacokinetic Assessment of Cooperative Efflux of the Multitargeted Kinase Inhibitor Ponatinib Across the Blood-Brain Barrier. The Journal of pharmacology and experimental therapeutics. 2018 05; 365(2):249-261. doi: 10.1124/jpet.117.246116. [PMID: 29440450]
  • Takeo Yasu, Kenji Momo, Shunsuke Kobayashi, Seiichirou Kuroda, Arinobu Tojo. Simple Determination of Plasma Ponatinib Concentration Using HPLC. Biological & pharmaceutical bulletin. 2018 Feb; 41(2):254-258. doi: 10.1248/bpb.b17-00806. [PMID: 29212964]
  • Maiko Abumiya, Masatomo Miura, Naoto Takahashi. Therapeutic drug monitoring of ponatinib using a simple high-performance liquid chromatography method in Japanese patients. Leukemia research. 2018 01; 64(?):42-45. doi: 10.1016/j.leukres.2017.11.012. [PMID: 29175427]
  • Janice K Laramy, Minjee Kim, Shiv K Gupta, Karen E Parrish, Shuangling Zhang, Katrina K Bakken, Brett L Carlson, Ann C Mladek, Daniel J Ma, Jann N Sarkaria, William F Elmquist. Heterogeneous Binding and Central Nervous System Distribution of the Multitargeted Kinase Inhibitor Ponatinib Restrict Orthotopic Efficacy in a Patient-Derived Xenograft Model of Glioblastoma. The Journal of pharmacology and experimental therapeutics. 2017 11; 363(2):136-147. doi: 10.1124/jpet.117.243477. [PMID: 28847917]
  • Anita Kort, Stéphanie van Hoppe, Rolf W Sparidans, Els Wagenaar, Jos H Beijnen, Alfred H Schinkel. Brain Accumulation of Ponatinib and Its Active Metabolite, N-Desmethyl Ponatinib, Is Limited by P-Glycoprotein (P-GP/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2). Molecular pharmaceutics. 2017 10; 14(10):3258-3268. doi: 10.1021/acs.molpharmaceut.7b00257. [PMID: 28880088]
  • De Lin, Rumen Kostov, Jeffrey T-J Huang, Colin J Henderson, C Roland Wolf. Novel Pathways of Ponatinib Disposition Catalyzed By CYP1A1 Involving Generation of Potentially Toxic Metabolites. The Journal of pharmacology and experimental therapeutics. 2017 10; 363(1):12-19. doi: 10.1124/jpet.117.243246. [PMID: 28882992]
  • Tobias Schwerd, Sumeet Pandey, Huei-Ting Yang, Katrin Bagola, Elisabeth Jameson, Jonathan Jung, Robin H Lachmann, Neil Shah, Smita Y Patel, Claire Booth, Heiko Runz, Gesche Düker, Ruth Bettels, Marianne Rohrbach, Subra Kugathasan, Helen Chapel, Satish Keshav, Abdul Elkadri, Nick Platt, Alexio M Muise, Sibylle Koletzko, Ramnik J Xavier, Thorsten Marquardt, Fiona Powrie, James E Wraith, Mads Gyrd-Hansen, Frances M Platt, Holm H Uhlig. Impaired antibacterial autophagy links granulomatous intestinal inflammation in Niemann-Pick disease type C1 and XIAP deficiency with NOD2 variants in Crohn's disease. Gut. 2017 06; 66(6):1060-1073. doi: 10.1136/gutjnl-2015-310382. [PMID: 26953272]
  • Yihua E Ye, Caroline N Woodward, Narayana I Narasimhan. Absorption, metabolism, and excretion of [14C]ponatinib after a single oral dose in humans. Cancer chemotherapy and pharmacology. 2017 03; 79(3):507-518. doi: 10.1007/s00280-017-3240-x. [PMID: 28184964]
  • Nicole Willemsen-Seegers, Joost C M Uitdehaag, Martine B W Prinsen, Judith R F de Vetter, Jos de Man, Masaaki Sawa, Yusuke Kawase, Rogier C Buijsman, Guido J R Zaman. Compound Selectivity and Target Residence Time of Kinase Inhibitors Studied with Surface Plasmon Resonance. Journal of molecular biology. 2017 02; 429(4):574-586. doi: 10.1016/j.jmb.2016.12.019. [PMID: 28043854]
  • Rolf W Sparidans, Anita Kort, Alfred H Schinkel, Jan H M Schellens, Jos H Beijnen. Liquid chromatography-tandem mass spectrometric assay for ponatinib and N-desmethyl ponatinib in mouse plasma. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2016 Jun; 1023-1024(?):24-9. doi: 10.1016/j.jchromb.2016.04.049. [PMID: 27179188]
  • Zechun Kang, Yunxia Ji, Guanghua Zhang, Yubei Qu, Liang Zhang, Wanglin Jiang. Ponatinib attenuates experimental pulmonary arterial hypertension by modulating Wnt signaling and vasohibin-2/vasohibin-1. Life sciences. 2016 Mar; 148(?):1-8. doi: 10.1016/j.lfs.2016.02.017. [PMID: 26860892]
  • Melis Kartal Yandim, Cagatay Ceylan, Efe Elmas, Yusuf Baran. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2016 Feb; 37(2):2365-78. doi: 10.1007/s13277-015-4015-9. [PMID: 26373734]
  • Adnan A Kadi, Hany W Darwish, Mohamed W Attwa, Sawsan M Amer. Validated LC-MS/MS Method for the Quantification of Ponatinib in Plasma: Application to Metabolic Stability. PloS one. 2016; 11(10):e0164967. doi: 10.1371/journal.pone.0164967. [PMID: 27764191]
  • Elias Jabbour, Hagop Kantarjian, Farhad Ravandi, Deborah Thomas, Xuelin Huang, Stefan Faderl, Naveen Pemmaraju, Naval Daver, Guillermo Garcia-Manero, Koji Sasaki, Jorge Cortes, Rebecca Garris, C Cameron Yin, Joseph D Khoury, Jeffrey Jorgensen, Zeev Estrov, Zachary Bohannan, Marina Konopleva, Tapan Kadia, Nitin Jain, Courtney DiNardo, William Wierda, Vicky Jeanis, Susan O'Brien. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. The Lancet. Oncology. 2015 Nov; 16(15):1547-1555. doi: 10.1016/s1470-2045(15)00207-7. [PMID: 26432046]
  • Narayana I Narasimhan, David J Dorer, Jeffrey Davis, Christopher D Turner, Daryl Sonnichsen. Evaluation of the effect of multiple doses of rifampin on the pharmacokinetics and safety of ponatinib in healthy subjects. Clinical pharmacology in drug development. 2015 09; 4(5):354-60. doi: 10.1002/cpdd.182. [PMID: 27137144]
  • Narayana I Narasimhan, David J Dorer, Jeffrey Davis, Christopher D Turner, Daryl Sonnichsen. Evaluation of the effect of multiple doses of lansoprazole on the pharmacokinetics and safety of ponatinib in healthy subjects. Clinical drug investigation. 2014 Oct; 34(10):723-9. doi: 10.1007/s40261-014-0225-y. [PMID: 25145453]
  • Narayana I Narasimhan, David J Dorer, Jeffrey Davis, Christopher D Turner, Thomas C Marbury, Daryl Sonnichsen. Evaluation of pharmacokinetics and safety of ponatinib in subjects with chronic hepatic impairment and matched healthy subjects. Cancer chemotherapy and pharmacology. 2014 Aug; 74(2):341-8. doi: 10.1007/s00280-014-2511-z. [PMID: 24934866]
  • N I Narasimhan, D J Dorer, K Niland, F Haluska, Daryl Sonnichsen. Effects of food on the pharmacokinetics of ponatinib in healthy subjects. Journal of clinical pharmacy and therapeutics. 2013 Dec; 38(6):440-4. doi: 10.1111/jcpt.12082. [PMID: 23888935]
  • Narayana I Narasimhan, David J Dorer, Katie Niland, Frank Haluska, Daryl Sonnichsen. Effects of ketoconazole on the pharmacokinetics of ponatinib in healthy subjects. Journal of clinical pharmacology. 2013 Sep; 53(9):974-81. doi: 10.1002/jcph.109. [PMID: 23801357]
  • Daryl Sonnichsen, David J Dorer, Jorge Cortes, Moshe Talpaz, Michael W Deininger, Neil P Shah, Hagop M Kantarjian, Dale Bixby, Michael J Mauro, Ian W Flinn, Jeffrey Litwin, Christopher D Turner, Frank G Haluska. Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies. Cancer chemotherapy and pharmacology. 2013 Jun; 71(6):1599-607. doi: 10.1007/s00280-013-2160-7. [PMID: 23609479]
  • Christian Grütter, Jeffrey R Simard, Svenja C Mayer-Wrangowski, Peter H Schreier, José Pérez-Martín, André Richters, Matthäus Getlik, Oliver Gutbrod, Christoph A Braun, Michael E Beck, Daniel Rauh. Targeting GSK3 from Ustilago maydis: type-II kinase inhibitors as potential antifungals. ACS chemical biology. 2012 Jul; 7(7):1257-67. doi: 10.1021/cb300128b. [PMID: 22545924]
  • Joseph M Gozgit, Matthew J Wong, Lauren Moran, Scott Wardwell, Qurish K Mohemmad, Narayana I Narasimhan, William C Shakespeare, Frank Wang, Tim Clackson, Victor M Rivera. Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Molecular cancer therapeutics. 2012 Mar; 11(3):690-9. doi: 10.1158/1535-7163.mct-11-0450. [PMID: 22238366]
  • . . . . doi: . [PMID: 32353859]